Budget impact and cost-utility analysis of universal infant rotavirus vaccination in Spain

Preventive Medicine

Volumn 61, Issue , 2014, Pages 116-121

  Imaz, Iñaki ^a,b   Rubio, Beltrán ^a   Cornejo, Ana M ^c   González Enríquez, Jesús ^a,b  

^a Instituto de Salud Carlos III Carlos III Institute for Health   (Spain)

^b REDISSEC ^*  (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Biomedical; Cost benefit analysis; Mass vaccination; Medical economics; Rotavirus; Technology assessment

Indexed keywords

ROTAVIRUS VACCINE; LIVE VACCINE;

ARTICLE; BUDGET; CHILD; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; EMERGENCY CARE; HEALTH CARE SYSTEM; HOSPITAL CARE; HUMAN; INFANT; PRESCHOOL CHILD; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; ROTAVIRUS; ROTAVIRUS INFECTION; SENSITIVITY ANALYSIS; SPAIN; VACCINATION; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; COST; ECONOMICS; FEMALE; GASTROENTERITIS; HEALTH CARE DELIVERY; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MASS COMMUNICATION; MASS IMMUNIZATION; MEDICATION COMPLIANCE; MORTALITY; MULTICENTER STUDY; PROBABILITY; PROCEDURES; PUBLIC HEALTH; ROTAVIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA; TRENDS;

BUDGETS; CHILD, PRESCHOOL; COHORT STUDIES; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DIFFUSION OF INNOVATION; FEMALE; GASTROENTERITIS; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; MARKOV CHAINS; MASS VACCINATION; MEDICATION ADHERENCE; MORTALITY; NATIONAL HEALTH PROGRAMS; QUALITY-ADJUSTED LIFE YEARS; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SPAIN; VACCINES, ATTENUATED;

EID: 84896096535     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2013.12.013     Document Type: Article

References (29)

1. Agencia Española de Medicamentos y Productos Sanitarios Nota informativa: detección de ADN de circovirus porcino tipo 1 y 2 (PCV-1 y PCV-2) en la vacuna frente a rotavirus Rotateq® 2010, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, (http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/calidad/2010/NI-circovirus-rotateq_junio-2010.htm. Access: 30-9-2011]).
2. Agencia Española de Medicamentos y Productos Sanitarios Nota informativa: Liberación de lotes de la vacuna Rotateq® 2010, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, (http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/calidad/2010/NI-circovirus-rotateq_noviembre-2010.htm. Access: 30-9-2011]).
3. Agencia Española de Medicamentos y Productos Sanitarios Nota informativa para profesionales sanitarios. Detección de ADN de un circovirus porcino 1 (PCV-1) en la vacuna Rotarix® 2010, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, (http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/calidad/2010/NI-circovirus_marzo-2010.htm. Access: 30-9-2011).
4. Atkins K.E., Shim E., Carroll S., Quilici S., Galvani A.P. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales. Vaccine 2012, 30:6766-6776.
5. Bilcke J., Van Damme P., Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care" disease impact in Belgium. Med. Decis. Making 2009, 29:33-50.
6. Brisson M., Senecal M., Drolet M., Mansi J.A. Health-related quality of life lost to rotavirus-associated gastroenteritis in children and their parents: a Canadian prospective study. Pediatr. Infect. Dis. J. 2010, 29:73-75.
7. CDC (Centers for Disease Control) Prevention, Rotavirus surveillance-worldwide, 2001-2008. MMWR 2011, 57:1255-1257.
8. Diez-Domingo J., Surinach N., Alcalde N., Betegon L., Largeron N., et al. Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain. BMC Public Health 2010, 10:469.
9. Eichler H.G., Kong S.X., Gerth W.C., Mavros P., Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 2004, 7:518-528.
10. Fischer T.K., Anh D.D., Antil L., Cat N.D., Kilgore P.E., et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J. Infect. Dis. 2005, 192:1720-1726.
11. Giaquinto C., Van Damme P., Huet F., Gothefors L., Van der Wielen M. Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the reveal study. J. Infect. Dis. 2007, 195(S1):S36-S44. on behalf of the REVEAL Study Group.
12. INE (Instituto Nacional de Estadística) Access 7-11-2012. http://www.ine.es.
13. Jit M., Bilcke J., Mangen M.J., Salo H., Melliez H., et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009, 27:6121-6128.
14. López-Bastida J., Oliva J., Antoñanzas F., García-Altés A., Gisbert R., et al. Spanish recommendations on economic evaluation of health technologies 2008, Ministerio de Sanidad y Consumo, Servicio de Evaluación del Servicio Canario de Salud, Madrid.
15. Mangen M.J., van Duynhoven Y.T., Vennema H., van Pelt W., Havelaar A.H., et al. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?. Vaccine 2010, 28:2624-2635.
16. Melliez H., Boelle P.Y., Baron S., Mouton Y., Yazdanpanah Y., et al. Effectiveness of childhood vaccination against rotavirus in sub-Saharan Africa: the case of Nigeria. Vaccine 2007, 25:298-305.
17. Melliez H., Levybruhl D., Boelle P.Y., Dervaux B., Baron S., et al. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008, 26:706-715.
18. Ministerio de Sanidad Coberturas de Vacunación (Access 7-11-2012). http://www.msc.es/.
19. NICE (National Institute for Health and Clinical Excellence) Guide to the Methods of Technology Appraisal 2008, NICE, London.
20. Parashar U.D., Burton A., Lanata C., Boschi-Pinto C., Shibuya K., et al. Global mortality associated with rotavirus disease among children in 2004. J. Infect. Dis. 2009, 200(S1):S9-S15.
21. Pérez-Rubio A., Luquero F.J., Eirós Bouza J.M., Castrodeza Sanz J.J., Bachiller Luque M.R., et al. Socio-economic modelling of rotavirus vaccination in Castilla y León, Spain. Le Infezione in Medicina 2011, 3:166-175.
22. Rozenbaum M.H., Mangen M.J., Giaquinto C., Wilschut J.C., Hak E., et al. Cost-effectiveness of rotavirus vaccination in The Netherlands; the results of a consensus model. BMC Public Health 2011, 11:462.
23. Sacristán J.A., Oliva J., Del LLano J., Prieto L., Pinto J.L. ¿Qué es una tecnología sanitaria eficiente en España?. Gac. Sanit. 2002, 16:334-343.
24. Takala A.K., Koskenniemi E., Joensuu J., Makela M., Vesikari T. Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. Clin. Infect. Dis. 1998, 27:272-282.
25. Tilson L., Jit M., Schmitz S., Walsh C., Garvey P., et al. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine 2011, 29:7463-7473.
26. Van Damme P., Giaquinto C., Huet F., Gothefors L., Maxwell M., et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J. Infect. Dis. 2007, 195(S1):S4-S16.
27. Velázquez F.R. Protective effects of natural rotavirus infection. Pediatr. Infect. Dis. J. 2009, 28(3S):S54-S56.
28. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 2006, 354(1):23-33.
29. Ward R.L., Bernstein D.I. Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group. J. Infect. Dis. 1994, 169:900-904.